Ikena Oncology, Inc.

Historical 13F Holders

Symbol
IKNA
CUSIP
45175G108
All holders as of
Q2 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 45175G108 since 12/18/2024, newest first.

Filer % of Class Filed
Orbimed Advisors LLC 13D/A Amendment 6
13.1% 4/29/2026
Event 4/14/2026
Deep Track Capital, LP 13G/A Amendment 1
0% 8/4/2025
Event 7/28/2025
Orbimed Advisors LLC 13D/A Amendment 5
6.9% 7/30/2025
Event 7/25/2025
Orbimed Advisors LLC 13D/A Amendment 4
16.7% 6/18/2025
Event 6/14/2025
BML Investment Partners, L.P. 13D
8.5% 6/16/2025
Event 6/16/2025
BML Investment Partners, L.P. 13G/A Amendment 1
7.6% 2/14/2025
Event 12/31/2024
Deep Track Capital, LP 13G
5.2% 2/14/2025
Event 2/7/2025
Biotechnology Value Fund L P 13G/A Amendment 4
8.3% 2/14/2025
Event 12/31/2024
Gilead Sciences, Inc. 13G/A Amendment 1 3.6% 2/13/2025
Event 12/31/2024
BML Investment Partners, L.P. 13G
7.6% 12/31/2024
Event 12/23/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q2 43 31.8 M $42.6 M
2025 Q1 47 32.7 M $41.9 M
2024 Q4 54 31.7 M $52.0 M
2024 Q3 59 28.4 M $49.1 M
2024 Q2 73 29.1 M $47.9 M
2024 Q1 61 30.2 M $42.9 M
2023 Q4 58 32.5 M $64.0 M
2023 Q3 59 32.7 M $142 M
2023 Q2 53 31.2 M $205 M
2023 Q1 40 25.0 M $86.2 M
2022 Q4 36 26.3 M $70.0 M
2022 Q3 44 27.5 M $97.8 M
2022 Q2 47 26.8 M $119 M
2022 Q1 50 27.5 M $168 M
2021 Q4 51 27.4 M $344 M
2021 Q3 40 20.9 M $272 M
2021 Q2 43 21.1 M $293 M
2021 Q1 28 19.3 M $539 M